Shionogi wins some, loses some as it books dolutegravir transfer impact
This article was originally published in Scrip
Executive Summary
Shionogi has now quantified the one-off accounting gain from the dissolution of its HIV joint venture with ViiV Healthcare and transfer of the integrase inhibitor dolutegravir: ¥41.1 billion ($444 million).